Table 1.
Characteristics of controls and NSCLC cases seperated by EGFR mutation status
| Male | Female | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Control | Case | Control | Case | |||||||||
| EGFRmut | Comparison with controls (P‐values) | EGFRwt | Comparison with controls (P‐values) | Comparison by mutation status (P‐values) | EGFRmut | Comparison with controls (P‐values) | EGFRwt | Comparison with controls (P‐values) | Comparison by mutation status (P‐values)* | |||
| n | 1080 | 46 | 170 | 685 | 76 | 61 | ||||||
| Age (SD) † | 62.6 ± 9.4 | 62.8 ± 9.7 | 62.5 ± 9.4 | 60.7 ± 11.0 | 63.5 ± 8.8 | 57.2 ± 12.6 | ||||||
| Smoking | ||||||||||||
| Never smoker | 254 (23.5%) | 14 (30.4%) | 0.702 | 7 (4.1%) | <0.001 | <0.001 | 594 (86.7%) | 69 (90.8%) | 0.24 | 43 (70.5%) | 0.003 | 0.004 |
| Former smoker | 415 (38.4%) | 15 (32.6%) | 57 (33.5%) | 26 (3.8%) | 4 (5.3%) | 5 (8.2%) | ||||||
| Current smoker | 408 (37.8%) | 17 (37.0%) | 106 (62.4%) | 65 (9.5%) | 3 (4.0%) | 13 (21.3%) | ||||||
| Unknown | 3 (0.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | ||||||
| 0 pack‐years | 255 (23.6%) | 14 (30.4%) | 0.563 | 7 (4.1%) | <0.001 | <0.001 | 594 (86.7%) | 69 (90.8%) | 0.018 | 43 (70.5%) | <0.001 | 0.009 |
| 1–40 pack‐years | 448 (41.5%) | 18 (39.1%) | 43 (25.3%) | 86 (12.6%) | 4 (5.3%) | 13 (21.3%) | ||||||
| >40 pack‐years | 352 (32.6%) | 14 (30.4%) | 115 (67.7%) | 3 (0.4%) | 2 (2.6%) | 5 (8.2%) | ||||||
| Unknown | 25 (2.3%) | 0 (0.0%) | 5 (2.9%) | 2 (0.3%) | 1 (1.3%) | 0 (0.0%) | ||||||
| Drinking | ||||||||||||
| Never drinker | 300 (27.8%) | 12 (26.1%) | 0.611 | 48 (28.2%) | 0.091 | 0.939 | 473 (69.1%) | 50 (65.8%) | 0.239 | 44 (72.1%) | 0.837 | 0.342 |
| Former drinker | 135 (12.5%) | 3 (6.5%) | 12 (7.1%) | 24 (3.5%) | 0 (0.0%) | 1 (1.6%) | ||||||
| Current drinker | 644 (59.6%) | 31 (67.4%) | 109 (64.1%) | 186 (27.2%) | 26 (34.2%) | 16 (26.2%) | ||||||
| Unknown | 1 (0.1%) | 0 (0.0%) | 1 (0.6%) | 2 (0.3%) | 0 (0.0%) | 0 (0.0%) | ||||||
| Histopathology | ||||||||||||
| Adenocarcinoma | 43 (93.5%) | 110 (64.7%) | 0.002 | 75 (98.7%) | 52 (85.3%) | 0.014 | ||||||
| Squamous cell carcinoma | 2 (4.4%) | 40 (23.5%) | 0 (0.0%) | 4 (6.6%) | ||||||||
| Large cell carcinoma | 1 (2.2%) | 13 (7.7%) | 0 (0.0%) | 4 (6.6%) | ||||||||
| Others | 0 (0.0%) | 7 (4.1%) | 1 (1.3%) | 1 (1.6%) | ||||||||
*
P‐values were calculated for homogeneity across three groups.
†
Mann–Whitney ranksum test was applied.
EGFR, epidermal growth factor receptor; SD, standard deviation.